ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) announced a poster presentation on the initial Phase 1b clinical data for ORIC-533 in patients with relapsed/refractory multiple myeloma at the 65th American Society of Hematology Annual Meeting. The study included a heavily pretreated patient population and ORIC-533 was well tolerated with no dose limiting toxicities. Preliminary evidence of enhanced CD8+ T-cell activation was seen at the highest dose levels tested and early evidence of single agent clinical activity was observed.